In spite of the upregulation of FARSA, DLBCL patients with high FARSA at a cutoff-low of 15% showed higher survival rates than patients with low FARSA (Figure 1B), implying a tumor suppressor-like role of FARSA in DLBCL. The gene discussed is FARSA; the disease is diffuse large B-cell lymphoma.